제이투케이바이오
Financials
Valuation Metrics
제이투케이바이오's Market Cap is ₩460B. At end of 2025 it was ₩503B. Ranked #1769 of 2,405 in KR market (top 74%), #1078 of 1,627 on KOSDAQ (top 66%), #188 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 81%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 45.96B KRW | KR#1,769/2,405 Sec#188/231 |
| Revenue | 43.90B KRW | KR#1,858/2,405 Sec#132/231 |
| Net Income | 5.81B KRW | KR#1,151/2,405 Sec#74/231 |
| Total Assets | 43.42B KRW | KR#2,249/2,405 Sec#206/231 |
| Net Assets | 36.57B KRW | KR#2,098/2,405 Sec#184/231 |
| Employees | 56 | KR#1,995/2,405 Sec#180/231 |
| Value | ||
| P/E | 7.91x | KR#703/2,405 Sec#32/231 |
| P/B | 1.26x | KR#1,708/2,405 Sec#115/231 |
| PEG | 0.09x | KR#420/2,405 Sec#20/231 |
| P/S | 1.05x | KR#1,469/2,405 Sec#84/231 |
| EV/EBITDA | 5.72x | KR#323/2,405 Sec#8/231 |
| FCF Yield | 4.41% | KR#912/2,405 Sec#54/231 |
| Profitability | ||
| ROE | 15.89% | KR#283/2,405 Sec#18/231 |
| ROA | 13.39% | KR#155/2,405 Sec#12/231 |
| Op. Margin | 14.80% | KR#310/2,405 Sec#29/231 |
| Revenue Growth | 50.99% | KR#203/2,405 Sec#28/231 |
| Earnings Growth | 85.09% | KR#432/2,405 Sec#30/231 |
| Financial Health | ||
| Debt Ratio | 18.72% | KR#331/2,405 Sec#45/231 |
| Total Debt | 400.0M KRW | KR#1,993/2,405 Sec#187/231 |
| FCF | 2.03B KRW | KR#1,082/2,405 Sec#77/231 |
| Cash | 9.21B KRW | KR#1,736/2,405 Sec#152/231 |
| Current Ratio | 4.11x | KR#362/2,405 Sec#57/231 |
| Net Debt/EBITDA | -1.36x | KR#313/2,405 Sec#15/231 |
| Dividend | ||
| Div. Yield | 3.21% | KR#632/2,405 Sec#29/231 |
| Div. Growth | 25.00% | KR#390/2,405 Sec#20/231 |
| Performance | ||
| 1Y Return | -9.13% | KR#764/2,405 Sec#43/231 |
| 1M Return | -13.15% | KR#1,426/2,405 Sec#143/231 |
| From 52W High | -38.88% | KR#713/2,405 Sec#48/231 |
| 1Y MDD | -39.17% | KR#536/2,405 Sec#37/231 |
| Trading | ||
| Volume | 17,411 shares | KR#1,569/2,405 Sec#155/231 |
| Trading Value | 133.2M KRW | KR#1,318/2,405 Sec#147/231 |
| Foreign Own. | 1.72% | KR#1,733/2,405 Sec#166/231 |
| Per Share | ||
| EPS | 994 KRW | KR#726/2,405 Sec#48/231 |
| BPS | 6,254 KRW | KR#1,345/2,405 Sec#93/231 |
Company Info
J2K Bio, established in 2016 and listed on KOSDAQ in March 2024, produces and sells cosmetic raw materials. The company is a cosmetic new material developer that swiftly meets client demands through innovative natural product methods and new material development using fermented microorganisms, offering a competitive edge. It focuses on developing new active ingredients derived from natural, organic, and biomaterials, providing safer alternatives to synthetic compounds. J2K Bio is headquartered in Cheongju-si, Chungcheongbuk-do.